Wednesday, June 10, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 30 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 8404638

    Dimer VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 26, 2013 · Expires Mar 21, 2033

    granted

  2. US 8388963

    Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  3. US 8357371

    Methods for treating hypercholesterolemia using antibodies to PCSK9

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 22, 2013 · Expires Jan 17, 2033

    granted

  4. US 8354103

    Human antibodies to human angiopoietin-like protein 4

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 15, 2013 · Expires Jan 10, 2033

    granted

  5. US 8343737

    Cell culture compositions capable of producing a VEGF-binding fusion polypeptide

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 1, 2013 · Expires Dec 27, 2032

    granted

  6. US 8338135

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  7. US 8337839

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  8. US 8329181

    Methods for treating B-cell lymphoma by administering an anti-CD20 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 11, 2012 · Expires Dec 6, 2032

    granted

  9. US 8309088

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 13, 2012 · Expires Nov 8, 2032

    granted

  10. US 8298532

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  11. US 8192741

    Method of treating rheumatoid arthritis with an anti-IL-6R antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 5, 2012 · Expires May 31, 2032

    granted

  12. US 8183014

    High affinity antibodies to human IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted May 22, 2012 · Expires May 17, 2032

    granted

  13. US 8158581

    IGF-1 fusion polypeptides and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 17, 2012 · Expires Apr 12, 2032

    granted

  14. US 8148107

    High affinity human antibodies to human nerve growth factor

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 3, 2012 · Expires Mar 29, 2032

    granted

  15. US 8114394

    Use of IL-1 antagonists to treat gout

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2012 · Expires Feb 9, 2032

    granted

  16. US 8110546

    VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 7, 2012 · Expires Feb 2, 2032

    granted

  17. US 8105805

    High affinity human antibodies to human IL-18 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 31, 2012 · Expires Jan 26, 2032

    granted

  18. US 8101724

    High-affinity human antibodies to human protease-activated receptor-2

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 24, 2012 · Expires Jan 19, 2032

    granted

  19. US 8097713

    Nucleic acid molecules which encode human anti-CD20 antibodies and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 17, 2012 · Expires Jan 12, 2032

    granted

  20. US 8092802

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2012 · Expires Jan 5, 2032

    granted

  21. US 8092803

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2012 · Expires Jan 5, 2032

    granted

  22. US 8084234

    Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 27, 2011 · Expires Dec 22, 2031

    granted

  23. US 8080248

    Method of treating rheumatoid arthritis with an IL-6R antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 20, 2011 · Expires Dec 15, 2031

    granted

  24. US 8075887

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 13, 2011 · Expires Dec 8, 2031

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.